

# **Clinical Policy: Vitamin D Testing Policy**

**Reference Number: TBD**

**Last Review Date: 8/25/20**

**Coding Implications**

**Revision Log**

**See Important Reminder at the end of this policy for important regulatory and legal information.**

## **Description:**

**Louisiana Healthcare Connections (LHCC) Operations Claims Reimbursement Policy**

**To ensure appropriate reimbursement for vitamin D testing is based upon medical necessity criteria.**

## **Policy/Criteria:**

**Effective TBD, It is the policy of LHCC that 25-hydroxy and 1, 25 dihydroxy vitamin D testing in healthy, asymptomatic adults and children is not medically necessary because these tests have not been demonstrated to have a clear clinical benefit.**

**Frequency limit for screenings will be no more than one per year.**

**For members diagnosed with Vitamin D deficiency there will be a limit of four per year.**

## **Coding Implications:**

**This policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage.**

**Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.**

**A claim submitted without a valid ICD-10-CM diagnosis code will be returned to the provider as an incomplete claim.**

## **Documentation:**

**Documentation must justify the test(s) chosen for a particular disease entity.**

<b><u>CPT® Codes</u></b>	<b><u>Description</u></b>
<b><u>82306</u></b>	<b><u>VITAMIN D; 25 HYDROXY, INCLUDES FRACTION(S), IF</u></b>
<b><u>82652</u></b>	<b><u>VITAMIN D; 1, 25 DIHYDROXY, INCLUDES FRACTION(S), IF</u></b>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

**ICD-10 CODES THAT SUPPORT MEDICAL NECESSITY FOR 82306:**

<b><u>The following ICD-10-CM codes support the medical necessity of CPT code 82306</u></b>	<b><u>DESCRIPTION</u></b>
<b><u>A15.0</u></b>	<b><u>Tuberculosis of lung</u></b>
<b><u>A15.4</u></b>	<b><u>Tuberculosis of intrathoracic lymph nodes</u></b>
<b><u>A15.5</u></b>	<b><u>Tuberculosis of larynx, trachea and bronchus</u></b>
<b><u>A15.6</u></b>	<b><u>Tuberculous pleurisy</u></b>
<b><u>A15.7</u></b>	<b><u>Primary respiratory tuberculosis</u></b>
<b><u>A15.8</u></b>	<b><u>Other respiratory tuberculosis</u></b>
<b><u>A17.0</u></b>	<b><u>Tuberculous meningitis</u></b>
<b><u>A17.1</u></b>	<b><u>Meningeal Tuberculoma</u></b>
<b><u>A17.81</u></b>	<b><u>Tuberculoma of brain and spinal cord</u></b>
<b><u>A17.82</u></b>	<b><u>Tuberculous meningoencephalitis</u></b>
<b><u>A17.83</u></b>	<b><u>Tuberculous neuritis</u></b>
<b><u>A17.89</u></b>	<b><u>Other tuberculosis of nervous system</u></b>
<b><u>A18.01</u></b>	<b><u>Tuberculosis of spine</u></b>
<b><u>A18.02</u></b>	<b><u>Tuberculous arthritis of other joints</u></b>
<b><u>A18.03</u></b>	<b><u>Tuberculosis of other bones</u></b>
<b><u>A18.09</u></b>	<b><u>Other musculoskeletal tuberculosis</u></b>
<b><u>A18.11</u></b>	<b><u>Tuberculosis of kidney and ureter</u></b>
<b><u>A18.12</u></b>	<b><u>Tuberculosis of bladder</u></b>
<b><u>A18.13</u></b>	<b><u>Tuberculosis of other urinary organs</u></b>
<b><u>A18.14</u></b>	<b><u>Tuberculosis of prostate</u></b>
<b><u>A18.15</u></b>	<b><u>Tuberculosis of other male genital organs</u></b>
<b><u>A18.16</u></b>	<b><u>Tuberculosis of cervix</u></b>
<b><u>A18.17</u></b>	<b><u>Tuberculous female pelvic inflammatory disease</u></b>
<b><u>A18.18</u></b>	<b><u>Tuberculosis of other female genital organs</u></b>
<b><u>A18.2</u></b>	<b><u>Tuberculous peripheral lymphadenopathy</u></b>
<b><u>A18.31</u></b>	<b><u>Tuberculous peritonitis</u></b>
<b><u>A18.32</u></b>	<b><u>Tuberculous enteritis</u></b>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<b><u>A18.39</u></b>	<b><u>Retroperitoneal tuberculosis</u></b>
<b><u>A18.4</u></b>	<b><u>Tuberculosis of skin and subcutaneous tissue</u></b>
<b><u>A18.51</u></b>	<b><u>Tuberculous episcleritis</u></b>
<b><u>A18.52</u></b>	<b><u>Tuberculous keratitis</u></b>
<b><u>A18.53</u></b>	<b><u>Tuberculous chorioretinitis</u></b>
<b><u>A18.54</u></b>	<b><u>Tuberculous iridocyclitis</u></b>
<b><u>A18.59</u></b>	<b><u>Other tuberculosis of eye</u></b>
<b><u>A18.6</u></b>	<b><u>Tuberculosis of (inner) (middle) ear</u></b>
<b><u>A18.7</u></b>	<b><u>Tuberculosis of adrenal glands</u></b>
<b><u>A18.81</u></b>	<b><u>Tuberculosis of thyroid gland</u></b>
<b><u>A18.82</u></b>	<b><u>Tuberculosis of other endocrine glands</u></b>
<b><u>A18.83</u></b>	<b><u>Tuberculosis of digestive tract organs, not elsewhere classified</u></b>
<b><u>A18.84</u></b>	<b><u>Tuberculosis of heart</u></b>
<b><u>A18.85</u></b>	<b><u>Tuberculosis of spleen</u></b>
<b><u>A18.89</u></b>	<b><u>Tuberculosis of other sites</u></b>
<b><u>A19.0</u></b>	<b><u>Acute miliary tuberculosis of a single specified site</u></b>
<b><u>A19.1</u></b>	<b><u>Acute miliary tuberculosis of multiple sites</u></b>
<b><u>A19.2</u></b>	<b><u>Acute miliary tuberculosis, unspecified</u></b>
<b><u>A19.8</u></b>	<b><u>Other miliary tuberculosis</u></b>
<b><u>B38.0</u></b>	<b><u>Acute pulmonary coccidioidomycosis</u></b>
<b><u>B38.1</u></b>	<b><u>Chronic pulmonary coccidioidomycosis</u></b>
<b><u>B38.3</u></b>	<b><u>Cutaneous coccidioidomycosis</u></b>
<b><u>B38.4</u></b>	<b><u>Coccidioidomycosis meningitis</u></b>
<b><u>B38.7</u></b>	<b><u>Disseminated coccidioidomycosis</u></b>
<b><u>B38.81</u></b>	<b><u>Prostatic coccidioidomycosis</u></b>
<b><u>B38.89</u></b>	<b><u>Other forms of coccidioidomycosis</u></b>
<b><u>B39.0</u></b>	<b><u>Acute pulmonary histoplasmosis capsulati</u></b>
<b><u>B39.1</u></b>	<b><u>Chronic pulmonary histoplasmosis capsulati</u></b>
<b><u>B39.3</u></b>	<b><u>Disseminated histoplasmosis capsulati</u></b>
<b><u>B39.5</u></b>	<b><u>Histoplasmosis duboisii</u></b>
<b><u>C82.01</u></b>	<b><u>Follicular lymphoma grade I, lymph nodes of head, face, and neck</u></b>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<b><u>C82.02</u></b>	<b><u>Follicular lymphoma grade I, intrathoracic lymph nodes</u></b>
<b><u>C82.03</u></b>	<b><u>Follicular lymphoma grade I, intra-abdominal lymph nodes</u></b>
<b><u>C82.04</u></b>	<b><u>Follicular lymphoma grade I, lymph nodes of axilla and upper limb</u></b>
<b><u>C82.05</u></b>	<b><u>Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb</u></b>
<b><u>C82.06</u></b>	<b><u>Follicular lymphoma grade I, intrapelvic lymph nodes</u></b>
<b><u>C82.07</u></b>	<b><u>Follicular lymphoma grade I, spleen</u></b>
<b><u>C82.08</u></b>	<b><u>Follicular lymphoma grade I, lymph nodes of multiple sites</u></b>
<b><u>C82.09</u></b>	<b><u>Follicular lymphoma grade I, extranodal and solid organ sites</u></b>
<b><u>C82.11</u></b>	<b><u>Follicular lymphoma grade II, lymph nodes of head, face, and neck</u></b>
<b><u>C82.12</u></b>	<b><u>Follicular lymphoma grade II, intrathoracic lymph nodes</u></b>
<b><u>C82.13</u></b>	<b><u>Follicular lymphoma grade II, intra-abdominal lymph nodes</u></b>
<b><u>C82.14</u></b>	<b><u>Follicular lymphoma grade II, lymph nodes of axilla and upper limb</u></b>
<b><u>C82.15</u></b>	<b><u>Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb</u></b>
<b><u>C82.16</u></b>	<b><u>Follicular lymphoma grade II, intrapelvic lymph nodes</u></b>
<b><u>C82.17</u></b>	<b><u>Follicular lymphoma grade II, spleen</u></b>
<b><u>C82.18</u></b>	<b><u>Follicular lymphoma grade II, lymph nodes of multiple sites</u></b>
<b><u>C82.19</u></b>	<b><u>Follicular lymphoma grade II, extranodal and solid organ sites</u></b>
<b><u>C82.21</u></b>	<b><u>Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck</u></b>
<b><u>C82.22</u></b>	<b><u>Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes</u></b>
<b><u>C82.23</u></b>	<b><u>Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes</u></b>
<b><u>C82.24</u></b>	<b><u>Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb</u></b>
<b><u>C82.25</u></b>	<b><u>Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb</u></b>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<u><b>C82.26</b></u>	<u><b>Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes</b></u>
<u><b>C82.27</b></u>	<u><b>Follicular lymphoma grade III, unspecified, spleen</b></u>
<u><b>C82.28</b></u>	<u><b>Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites</b></u>
<u><b>C82.29</b></u>	<u><b>Follicular lymphoma grade III, unspecified, extranodal and solid organ sites</b></u>
<u><b>C82.31</b></u>	<u><b>Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck</b></u>
<u><b>C82.32</b></u>	<u><b>Follicular lymphoma grade IIIa, intrathoracic lymph nodes</b></u>
<u><b>C82.33</b></u>	<u><b>Follicular lymphoma grade IIIa, intra-abdominal lymph nodes</b></u>
<u><b>C82.34</b></u>	<u><b>Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb</b></u>
<u><b>C82.35</b></u>	<u><b>Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb</b></u>
<u><b>C82.36</b></u>	<u><b>Follicular lymphoma grade IIIa, intrapelvic lymph nodes</b></u>
<u><b>C82.37</b></u>	<u><b>Follicular lymphoma grade IIIa, spleen</b></u>
<u><b>C82.38</b></u>	<u><b>Follicular lymphoma grade IIIa, lymph nodes of multiple sites</b></u>
<u><b>C82.39</b></u>	<u><b>Follicular lymphoma grade IIIa, extranodal and solid organ sites</b></u>
<u><b>C82.41</b></u>	<u><b>Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck</b></u>
<u><b>C82.42</b></u>	<u><b>Follicular lymphoma grade IIIb, intrathoracic lymph nodes</b></u>
<u><b>C82.43</b></u>	<u><b>Follicular lymphoma grade IIIb, intra-abdominal lymph nodes</b></u>
<u><b>C82.44</b></u>	<u><b>Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb</b></u>
<u><b>C82.45</b></u>	<u><b>Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb</b></u>
<u><b>C82.46</b></u>	<u><b>Follicular lymphoma grade IIIb, intrapelvic lymph nodes</b></u>
<u><b>C82.47</b></u>	<u><b>Follicular lymphoma grade IIIb, spleen</b></u>
<u><b>C82.48</b></u>	<u><b>Follicular lymphoma grade IIIb, lymph nodes of multiple sites</b></u>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<b><u>C82.49</u></b>	<b><u>Follicular lymphoma grade IIIb, extranodal and solid organ sites</u></b>
<b><u>C82.51</u></b>	<b><u>Diffuse follicle center lymphoma, lymph nodes of head, face, and neck</u></b>
<b><u>C82.52</u></b>	<b><u>Diffuse follicle center lymphoma, intrathoracic lymph nodes</u></b>
<b><u>C82.53</u></b>	<b><u>Diffuse follicle center lymphoma, intra-abdominal lymph nodes</u></b>
<b><u>C82.54</u></b>	<b><u>Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb</u></b>
<b><u>C82.55</u></b>	<b><u>Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb</u></b>
<b><u>C82.56</u></b>	<b><u>Diffuse follicle center lymphoma, intrapelvic lymph nodes</u></b>
<b><u>C82.57</u></b>	<b><u>Diffuse follicle center lymphoma, spleen</u></b>
<b><u>C82.58</u></b>	<b><u>Diffuse follicle center lymphoma, lymph nodes of multiple sites</u></b>
<b><u>C82.59</u></b>	<b><u>Diffuse follicle center lymphoma, extranodal and solid organ sites</u></b>
<b><u>C82.61</u></b>	<b><u>Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck</u></b>
<b><u>C82.62</u></b>	<b><u>Cutaneous follicle center lymphoma, intrathoracic lymph nodes</u></b>
<b><u>C82.63</u></b>	<b><u>Cutaneous follicle center lymphoma, intra-abdominal lymph nodes</u></b>
<b><u>C82.64</u></b>	<b><u>Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb</u></b>
<b><u>C82.65</u></b>	<b><u>Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb</u></b>
<b><u>C82.66</u></b>	<b><u>Cutaneous follicle center lymphoma, intrapelvic lymph nodes</u></b>
<b><u>C82.67</u></b>	<b><u>Cutaneous follicle center lymphoma, spleen</u></b>
<b><u>C82.68</u></b>	<b><u>Cutaneous follicle center lymphoma, lymph nodes of multiple sites</u></b>
<b><u>C82.69</u></b>	<b><u>Cutaneous follicle center lymphoma, extranodal and solid organ sites</u></b>
<b><u>C82.81</u></b>	<b><u>Other types of follicular lymphoma, lymph nodes of head, face, and neck</u></b>
<b><u>C82.82</u></b>	<b><u>Other types of follicular lymphoma, intrathoracic lymph nodes</u></b>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<u><b>C82.83</b></u>	<u><b>Other types of follicular lymphoma, intra-abdominal lymph nodes</b></u>
<u><b>C82.84</b></u>	<u><b>Other types of follicular lymphoma, lymph nodes of axilla and upper limb</b></u>
<u><b>C82.85</b></u>	<u><b>Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb</b></u>
<u><b>C82.86</b></u>	<u><b>Other types of follicular lymphoma, intrapelvic lymph nodes</b></u>
<u><b>C82.87</b></u>	<u><b>Other types of follicular lymphoma, spleen</b></u>
<u><b>C82.88</b></u>	<u><b>Other types of follicular lymphoma, lymph nodes of multiple sites</b></u>
<u><b>C82.89</b></u>	<u><b>Other types of follicular lymphoma, extranodal and solid organ sites</b></u>
<u><b>C82.91</b></u>	<u><b>Follicular lymphoma, unspecified, lymph nodes of head, face, and neck</b></u>
<u><b>C82.92</b></u>	<u><b>Follicular lymphoma, unspecified, intrathoracic lymph nodes</b></u>
<u><b>C82.93</b></u>	<u><b>Follicular lymphoma, unspecified, intra-abdominal lymph nodes</b></u>
<u><b>C82.94</b></u>	<u><b>Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb</b></u>
<u><b>C82.95</b></u>	<u><b>Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb</b></u>
<u><b>C82.96</b></u>	<u><b>Follicular lymphoma, unspecified, intrapelvic lymph nodes</b></u>
<u><b>C82.97</b></u>	<u><b>Follicular lymphoma, unspecified, spleen</b></u>
<u><b>C82.98</b></u>	<u><b>Follicular lymphoma, unspecified, lymph nodes of multiple sites</b></u>
<u><b>C82.99</b></u>	<u><b>Follicular lymphoma, unspecified, extranodal and solid organ sites</b></u>
<u><b>D80.0</b></u>	<u><b>Hereditary hypogammaglobulinemia</b></u>
<u><b>D80.1</b></u>	<u><b>Nonfamilial hypogammaglobulinemia</b></u>
<u><b>D80.2</b></u>	<u><b>Selective deficiency of immunoglobulin A [IgA]</b></u>
<u><b>D80.3</b></u>	<u><b>Selective deficiency of immunoglobulin G [IgG] subclasses</b></u>
<u><b>D80.4</b></u>	<u><b>Selective deficiency of immunoglobulin M [IgM]</b></u>
<u><b>D80.5</b></u>	<u><b>Immunodeficiency with increased immunoglobulin M [IgM]</b></u>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<u><b>D80.6</b></u>	<u><b>Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia</b></u>
<u><b>D80.7</b></u>	<u><b>Transient hypogammaglobulinemia of infancy</b></u>
<u><b>D80.8</b></u>	<u><b>Other immunodeficiencies with predominantly antibody defects</b></u>
<u><b>D80.9</b></u>	<u><b>Immunodeficiency with predominantly antibody defects, unspecified</b></u>
<u><b>D89.810</b></u>	<u><b>Acute graft-versus-host disease</b></u>
<u><b>D89.811</b></u>	<u><b>Chronic graft-versus-host disease</b></u>
<u><b>D89.812</b></u>	<u><b>Acute on chronic graft-versus-host disease</b></u>
<u><b>D89.813</b></u>	<u><b>Graft-versus-host disease, unspecified</b></u>
<u><b>E20.0</b></u>	<u><b>Idiopathic hypoparathyroidism</b></u>
<u><b>E20.8</b></u>	<u><b>Other hypoparathyroidism</b></u>
<u><b>E20.9</b></u>	<u><b>Hypoparathyroidism, unspecified</b></u>
<u><b>E21.0</b></u>	<u><b>Primary hyperparathyroidism</b></u>
<u><b>E21.1</b></u>	<u><b>Secondary hyperparathyroidism, not elsewhere classified</b></u>
<u><b>E21.2</b></u>	<u><b>Other hyperparathyroidism</b></u>
<u><b>E21.3</b></u>	<u><b>Hyperparathyroidism, unspecified</b></u>
<u><b>C82.89</b></u>	<u><b>Other types of follicular lymphoma, extranodal and solid organ sites</b></u>
<u><b>C82.91</b></u>	<u><b>Follicular lymphoma, unspecified, lymph nodes of head, face, and neck</b></u>
<u><b>C82.92</b></u>	<u><b>Follicular lymphoma, unspecified, intrathoracic lymph nodes</b></u>
<u><b>C82.93</b></u>	<u><b>Follicular lymphoma, unspecified, intra-abdominal lymph nodes</b></u>
<u><b>C82.94</b></u>	<u><b>Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb</b></u>
<u><b>C82.95</b></u>	<u><b>Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb</b></u>
<u><b>C82.96</b></u>	<u><b>Follicular lymphoma, unspecified, intrapelvic lymph nodes</b></u>
<u><b>C82.97</b></u>	<u><b>Follicular lymphoma, unspecified, spleen</b></u>
<u><b>C82.98</b></u>	<u><b>Follicular lymphoma, unspecified, lymph nodes of multiple sites</b></u>



## CLINICAL POLICY

### Vitamin D Testing Policy

<u><b>C82.99</b></u>	<u><b>Follicular lymphoma, unspecified, extranodal and solid organ sites</b></u>
<u><b>D80.0</b></u>	<u><b>Hereditary hypogammaglobulinemia</b></u>
<u><b>D80.1</b></u>	<u><b>Nonfamilial hypogammaglobulinemia</b></u>
<u><b>D80.2</b></u>	<u><b>Selective deficiency of immunoglobulin A [IgA]</b></u>
<u><b>D80.3</b></u>	<u><b>Selective deficiency of immunoglobulin G [IgG] subclasses</b></u>
<u><b>D80.4</b></u>	<u><b>Selective deficiency of immunoglobulin M [IgM]</b></u>
<u><b>D80.5</b></u>	<u><b>Immunodeficiency with increased immunoglobulin M [IgM]</b></u>
<u><b>D80.6</b></u>	<u><b>Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia</b></u>
<u><b>D80.7</b></u>	<u><b>Transient hypogammaglobulinemia of infancy</b></u>
<u><b>D80.8</b></u>	<u><b>Other immune deficiencies with predominantly antibody defects</b></u>
<u><b>D80.9</b></u>	<u><b>Immunodeficiency with predominantly antibody defects, unspecified</b></u>
<u><b>D89.810</b></u>	<u><b>Acute graft-versus-host disease</b></u>
<u><b>D89.811</b></u>	<u><b>Chronic graft-versus-host disease</b></u>
<u><b>D89.812</b></u>	<u><b>Acute on chronic graft-versus-host disease</b></u>
<u><b>D89.813</b></u>	<u><b>Graft-versus-host disease, unspecified</b></u>
<u><b>E20.0</b></u>	<u><b>Idiopathic hypoparathyroidism</b></u>
<u><b>E20.8</b></u>	<u><b>Other hypoparathyroidism</b></u>
<u><b>E20.9</b></u>	<u><b>Hypoparathyroidism, unspecified</b></u>
<u><b>E21.0</b></u>	<u><b>Primary hyperparathyroidism</b></u>
<u><b>E21.1</b></u>	<u><b>Secondary hyperparathyroidism, not elsewhere classified</b></u>
<u><b>E21.2</b></u>	<u><b>Other hyperparathyroidism</b></u>
<u><b>E21.3</b></u>	<u><b>Hyperparathyroidism, unspecified</b></u>
<u><b>E41</b></u>	<u><b>Nutritional marasmus</b></u>
<u><b>E43</b></u>	<u><b>Unspecified severe protein-calorie malnutrition</b></u>
<u><b>E55.0</b></u>	<u><b>Rickets, active</b></u>
<u><b>E55.9*</b></u>	<u><b>Vitamin D deficiency, unspecified</b></u>
<u><b>E66.01</b></u>	<u><b>Morbid (severe) obesity due to excess calories</b></u>
<u><b>E66.09</b></u>	<u><b>Other obesity due to excess calories</b></u>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<u><b>E66.1</b></u>	<u><b>Drug-induced obesity</b></u>
<u><b>E66.2</b></u>	<u><b>Morbid (severe) obesity with alveolar hypoventilation</b></u>
<u><b>E66.8</b></u>	<u><b>Other obesity</b></u>
<u><b>E67.3</b></u>	<u><b>Hypervitaminosis D</b></u>
<u><b>E67.8</b></u>	<u><b>Other specified hyperalimentation</b></u>
<u><b>E68</b></u>	<u><b>Sequelae of hyperalimentation</b></u>
<u><b>E83.30</b></u>	<u><b>Disorder of phosphorus metabolism, unspecified</b></u>
<u><b>E83.31</b></u>	<u><b>Familial hypophosphatemia</b></u>
<u><b>E83.32</b></u>	<u><b>Hereditary vitamin D-dependent rickets (type 1) (type 2)</b></u>
<u><b>E83.39</b></u>	<u><b>Other disorders of phosphorus metabolism</b></u>
<u><b>E83.50*</b></u>	<u><b>Unspecified disorder of calcium metabolism</b></u>
<u><b>E83.51</b></u>	<u><b>Hypocalcemia</b></u>
<u><b>E83.52</b></u>	<u><b>Hypercalcemia</b></u>
<u><b>E84.0</b></u>	<u><b>Cystic fibrosis with pulmonary manifestations</b></u>
<u><b>E84.11</b></u>	<u><b>Meconium ileus in cystic fibrosis</b></u>
<u><b>E84.19</b></u>	<u><b>Cystic fibrosis with other intestinal manifestations</b></u>
<u><b>E84.8</b></u>	<u><b>Cystic fibrosis with other manifestations</b></u>
<u><b>E84.9</b></u>	<u><b>Cystic fibrosis, unspecified</b></u>
<u><b>E89.2</b></u>	<u><b>Post procedural hypoparathyroidism</b></u>
<u><b>E89.820</b></u>	<u><b>Post procedural hematoma of an endocrine system organ or structure following an endocrine system procedure</b></u>
<u><b>E89.821</b></u>	<u><b>Post procedural hematoma of an endocrine system organ or structure following other procedure</b></u>
<u><b>E89.822</b></u>	<u><b>Post procedural seroma of an endocrine system organ or structure following an endocrine system procedure</b></u>
<u><b>E89.823</b></u>	<u><b>Post procedural seroma of an endocrine system organ or structure following other procedure</b></u>
<u><b>J63.2</b></u>	<u><b>Berylliosis</b></u>
<u><b>K50.00</b></u>	<u><b>Crohn's disease of small intestine without complications</b></u>
<u><b>K50.011</b></u>	<u><b>Crohn's disease of small intestine with rectal bleeding</b></u>
<u><b>K50.012</b></u>	<u><b>Crohn's disease of small intestine with intestinal obstruction</b></u>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<b><u>K50.013</u></b>	<b><u>Crohn's disease of small intestine with fistula</u></b>
<b><u>K50.014</u></b>	<b><u>Crohn's disease of small intestine with abscess</u></b>
<b><u>K50.018</u></b>	<b><u>Crohn's disease of small intestine with other complication</u></b>
<b><u>K50.019</u></b>	<b><u>Crohn's disease of small intestine with unspecified complications</u></b>
<b><u>K50.10</u></b>	<b><u>Crohn's disease of large intestine without complications</u></b>
<b><u>K50.111</u></b>	<b><u>Crohn's disease of large intestine with rectal bleeding</u></b>
<b><u>K50.112</u></b>	<b><u>Crohn's disease of large intestine with intestinal obstruction</u></b>
<b><u>K50.113</u></b>	<b><u>Crohn's disease of large intestine with fistula</u></b>
<b><u>K50.114</u></b>	<b><u>Crohn's disease of large intestine with abscess</u></b>
<b><u>K50.118</u></b>	<b><u>Crohn's disease of large intestine with other complication</u></b>
<b><u>K50.119</u></b>	<b><u>Crohn's disease of large intestine with unspecified complications</u></b>
<b><u>K50.80</u></b>	<b><u>Crohn's disease of both small and large intestine without complications</u></b>
<b><u>K50.811</u></b>	<b><u>Crohn's disease of both small and large intestine with rectal bleeding</u></b>
<b><u>K50.812</u></b>	<b><u>Crohn's disease of both small and large intestine with intestinal obstruction</u></b>
<b><u>K50.813</u></b>	<b><u>Crohn's disease of both small and large intestine with fistula</u></b>
<b><u>K50.814</u></b>	<b><u>Crohn's disease of both small and large intestine with abscess</u></b>
<b><u>K50.818</u></b>	<b><u>Crohn's disease of both small and large intestine with other complication</u></b>
<b><u>K50.819</u></b>	<b><u>Crohn's disease of both small and large intestine with unspecified complications</u></b>
<b><u>K50.90</u></b>	<b><u>Crohn's disease, unspecified, without complications</u></b>
<b><u>K50.911</u></b>	<b><u>Crohn's disease, unspecified, with rectal bleeding</u></b>
<b><u>K50.912</u></b>	<b><u>Crohn's disease, unspecified, with intestinal obstruction</u></b>
<b><u>K50.913</u></b>	<b><u>Crohn's disease, unspecified, with fistula</u></b>
<b><u>K50.914</u></b>	<b><u>Crohn's disease, unspecified, with abscess</u></b>
<b><u>K50.918</u></b>	<b><u>Crohn's disease, unspecified, with other complication</u></b>
<b><u>K52.0</u></b>	<b><u>Gastroenteritis and colitis due to radiation</u></b>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<b><u>K70.2</u></b>	<b><u>Alcoholic fibrosis and sclerosis of liver</u></b>
<b><u>K70.30</u></b>	<b><u>Alcoholic cirrhosis of liver without ascites</u></b>
<b><u>K70.31</u></b>	<b><u>Alcoholic cirrhosis of liver with ascites</u></b>
<b><u>K74.1</u></b>	<b><u>Hepatic sclerosis</u></b>
<b><u>K74.2</u></b>	<b><u>Hepatic fibrosis with hepatic sclerosis</u></b>
<b><u>K74.3</u></b>	<b><u>Primary biliary cirrhosis</u></b>
<b><u>K74.4</u></b>	<b><u>Secondary biliary cirrhosis</u></b>
<b><u>K74.5</u></b>	<b><u>Biliary cirrhosis, unspecified</u></b>
<b><u>K74.60</u></b>	<b><u>Unspecified cirrhosis of liver</u></b>
<b><u>K74.69</u></b>	<b><u>Other cirrhosis of liver</u></b>
<b><u>K76.9</u></b>	<b><u>Liver disease, unspecified</u></b>
<b><u>K83.5</u></b>	<b><u>Biliary cyst</u></b>
<b><u>K83.8</u></b>	<b><u>Other specified diseases of biliary tract</u></b>
<b><u>K85.00</u></b>	<b><u>Idiopathic acute pancreatitis without necrosis or infection</u></b>
<b><u>K85.01</u></b>	<b><u>Idiopathic acute pancreatitis with uninfected necrosis</u></b>
<b><u>K85.02</u></b>	<b><u>Idiopathic acute pancreatitis with infected necrosis</u></b>
<b><u>K85.10</u></b>	<b><u>Biliary acute pancreatitis without necrosis or infection</u></b>
<b><u>K85.11</u></b>	<b><u>Biliary acute pancreatitis with uninfected necrosis</u></b>
<b><u>K85.12</u></b>	<b><u>Biliary acute pancreatitis with infected necrosis</u></b>
<b><u>K85.20</u></b>	<b><u>Alcohol induced acute pancreatitis without necrosis or infection</u></b>
<b><u>K85.21</u></b>	<b><u>Alcohol induced acute pancreatitis with uninfected necrosis</u></b>
<b><u>K85.22</u></b>	<b><u>Alcohol induced acute pancreatitis with infected necrosis</u></b>
<b><u>K85.30</u></b>	<b><u>Drug induced acute pancreatitis without necrosis or infection</u></b>
<b><u>K85.31</u></b>	<b><u>Drug induced acute pancreatitis with uninfected necrosis</u></b>
<b><u>K85.32</u></b>	<b><u>Drug induced acute pancreatitis with infected necrosis</u></b>
<b><u>K85.80</u></b>	<b><u>Other acute pancreatitis without necrosis or infection</u></b>
<b><u>K85.81</u></b>	<b><u>Other acute pancreatitis with uninfected necrosis</u></b>
<b><u>K85.82</u></b>	<b><u>Other acute pancreatitis with infected necrosis</u></b>

**CLINICAL POLICY**  
**Vitamin D Testing Policy**

<b><u>K85.90</u></b>	<b><u>Acute pancreatitis without necrosis or infection, unspecified</u></b>
<b><u>K85.91</u></b>	<b><u>Acute pancreatitis with uninfected necrosis, unspecified</u></b>
<b><u>K85.92</u></b>	<b><u>Acute pancreatitis with infected necrosis, unspecified</u></b>
<b><u>K86.0</u></b>	<b><u>Alcohol-induced chronic pancreatitis</u></b>
<b><u>K86.1</u></b>	<b><u>Other chronic pancreatitis</u></b>
<b><u>K86.2</u></b>	<b><u>Cyst of pancreas</u></b>
<b><u>K86.3</u></b>	<b><u>Pseudocyst of pancreas</u></b>
<b><u>K86.81</u></b>	<b><u>Exocrine pancreatic insufficiency</u></b>
<b><u>K86.89</u></b>	<b><u>Other specified diseases of pancreas</u></b>
<b><u>K90.0</u></b>	<b><u>Celiac disease</u></b>
<b><u>K90.1</u></b>	<b><u>Tropical sprue</u></b>
<b><u>K90.2</u></b>	<b><u>Blind loop syndrome, not elsewhere classified</u></b>
<b><u>K90.3</u></b>	<b><u>Pancreatic steatorrhea</u></b>
<b><u>K90.41</u></b>	<b><u>Non-celiac gluten sensitivity</u></b>
<b><u>K90.49</u></b>	<b><u>Malabsorption due to intolerance, not elsewhere classified</u></b>
<b><u>K90.89</u></b>	<b><u>Other intestinal malabsorption</u></b>
<b><u>K90.9</u></b>	<b><u>Intestinal malabsorption, unspecified</u></b>
<b><u>K91.2</u></b>	<b><u>Postsurgical malabsorption, not elsewhere classified</u></b>
<b><u>L40.0</u></b>	<b><u>Psoriasis vulgaris</u></b>
<b><u>L40.1</u></b>	<b><u>Generalized pustular psoriasis</u></b>
<b><u>L40.2</u></b>	<b><u>Acrodermatitis continua</u></b>
<b><u>L40.3</u></b>	<b><u>Pustulosis palmaris et plantaris</u></b>
<b><u>L40.4</u></b>	<b><u>Guttate psoriasis</u></b>
<b><u>L40.50</u></b>	<b><u>Arthropathic psoriasis, unspecified</u></b>
<b><u>L40.51</u></b>	<b><u>Distal interphalangeal psoriatic arthropathy</u></b>
<b><u>L40.52</u></b>	<b><u>Psoriatic arthritis mutilans</u></b>
<b><u>L40.53</u></b>	<b><u>Psoriatic spondylitis</u></b>
<b><u>L40.54</u></b>	<b><u>Psoriatic juvenile arthropathy</u></b>
<b><u>L40.59</u></b>	<b><u>Other psoriatic arthropathy</u></b>
<b><u>L40.8</u></b>	<b><u>Other psoriasis</u></b>
<b><u>L40.9</u></b>	<b><u>Psoriasis, unspecified</u></b>

## CLINICAL POLICY

### Vitamin D Testing Policy

<b><u>M80.00XA - M80.88XS</u></b>	<b><u>Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture</u></b> <b><u>- Other osteoporosis with current pathological fracture, vertebra(e), sequela</u></b>
<b><u>M81.0</u></b>	<b><u>Age-related osteoporosis without current pathological fracture</u></b>
<b><u>M81.6</u></b>	<b><u>Localized osteoporosis [Lequesne]</u></b>
<b><u>M81.8</u></b>	<b><u>Other osteoporosis without current pathological fracture</u></b>
<b><u>M83.0</u></b>	<b><u>Puerperal osteomalacia</u></b>
<b><u>M83.1</u></b>	<b><u>Senile osteomalacia</u></b>
<b><u>M83.2</u></b>	<b><u>Adult osteomalacia due to malabsorption</u></b>
<b><u>M83.3</u></b>	<b><u>Adult osteomalacia due to malnutrition</u></b>
<b><u>M83.4</u></b>	<b><u>Aluminum bone disease</u></b>
<b><u>M83.5</u></b>	<b><u>Other drug-induced osteomalacia in adults</u></b>
<b><u>M83.8</u></b>	<b><u>Other adult osteomalacia</u></b>
<b><u>M83.9</u></b>	<b><u>Adult osteomalacia, unspecified</u></b>
<b><u>M85.80*</u></b>	<b><u>Other specified disorders of bone density and structure, unspecified site</u></b>
<b><u>M85.831*</u></b>	<b><u>Other specified disorders of bone density and structure, right forearm</u></b>
<b><u>M85.832*</u></b>	<b><u>Other specified disorders of bone density and structure, left forearm</u></b>
<b><u>M85.839*</u></b>	<b><u>Other specified disorders of bone density and structure, unspecified forearm</u></b>
<b><u>M85.851*</u></b>	<b><u>Other specified disorders of bone density and structure, right thigh</u></b>
<b><u>M85.852*</u></b>	<b><u>Other specified disorders of bone density and structure, left thigh</u></b>
<b><u>M85.859*</u></b>	<b><u>Other specified disorders of bone density and structure, unspecified thigh</u></b>
<b><u>M85.88*</u></b>	<b><u>Other specified disorders of bone density and structure, other site</u></b>
<b><u>M85.89*</u></b>	<b><u>Other specified disorders of bone density and structure, multiple sites</u></b>
<b><u>M85.9*</u></b>	<b><u>Disorder of bone density and structure, unspecified</u></b>
<b><u>M89.9*</u></b>	<b><u>Disorder of bone, unspecified</u></b>
<b><u>N18.3</u></b>	<b><u>Chronic kidney disease, stage 3 (moderate)</u></b>

## CLINICAL POLICY

### Vitamin D Testing Policy

<b><u>N18.4</u></b>	<b><u>Chronic kidney disease, stage 4 (severe)</u></b>
<b><u>N18.5</u></b>	<b><u>Chronic kidney disease, stage 5</u></b>
<b><u>N18.6</u></b>	<b><u>End stage renal disease</u></b>
<b><u>N25.81</u></b>	<b><u>Secondary hyperparathyroidism of renal origin</u></b>
<b><u>Q78.2</u></b>	<b><u>Osteopetrosis</u></b>
<b><u>Z68.30</u></b>	<b><u>Body mass index (BMI) 30.0-30.9, adult</u></b>
<b><u>Z68.31</u></b>	<b><u>Body mass index (BMI) 31.0-31.9, adult</u></b>
<b><u>Z68.32</u></b>	<b><u>Body mass index (BMI) 32.0-32.9, adult</u></b>
<b><u>Z68.33</u></b>	<b><u>Body mass index (BMI) 33.0-33.9, adult</u></b>
<b><u>Z68.34</u></b>	<b><u>Body mass index (BMI) 34.0-34.9, adult</u></b>
<b><u>Z68.35</u></b>	<b><u>Body mass index (BMI) 35.0-35.9, adult</u></b>
<b><u>Z68.36</u></b>	<b><u>Body mass index (BMI) 36.0-36.9, adult</u></b>
<b><u>Z68.37</u></b>	<b><u>Body mass index (BMI) 37.0-37.9, adult</u></b>
<b><u>Z68.38</u></b>	<b><u>Body mass index (BMI) 38.0-38.9, adult</u></b>
<b><u>Z68.39</u></b>	<b><u>Body mass index (BMI) 39.0-39.9, adult</u></b>
<b><u>Z68.41</u></b>	<b><u>Body mass index (BMI) 40.0-44.9, adult</u></b>
<b><u>Z68.42</u></b>	<b><u>Body mass index (BMI) 45.0-49.9, adult</u></b>
<b><u>Z68.43</u></b>	<b><u>Body mass index (BMI) 50.0-59.9, adult</u></b>
<b><u>Z68.44</u></b>	<b><u>Body mass index (BMI) 60.0-69.9, adult</u></b>
<b><u>Z68.45</u></b>	<b><u>Body mass index (BMI) 70 or greater, adult</u></b>
<b><u>Z79.3</u></b>	<b><u>Long term (current) use of hormonal contraceptives</u></b>
<b><u>Z79.4</u></b>	<b><u>Long term (current) use of insulin</u></b>
<b><u>Z79.51</u></b>	<b><u>Long term (current) use of inhaled steroids</u></b>
<b><u>Z79.52</u></b>	<b><u>Long term (current) use of systemic steroids</u></b>
<b><u>Z79.810</u></b>	<b><u>Long term (current) use of selective estrogen receptor modulators (SERMs)</u></b>
<b><u>Z79.811</u></b>	<b><u>Long term (current) use of aromatase inhibitors</u></b>
<b><u>Z79.818</u></b>	<b><u>Long term (current) use of other agents affecting estrogen receptors and estrogen levels</u></b>
<b><u>Z79.82</u></b>	<b><u>Long term (current) use of aspirin</u></b>
<b><u>Z79.83</u></b>	<b><u>Long term (current) use of bisphosphonates</u></b>
<b><u>Z79.84</u></b>	<b><u>Long term (current) use of oral hypoglycemic drugs</u></b>
<b><u>Z79.890</u></b>	<b><u>Hormone replacement therapy</u></b>

## CLINICAL POLICY

### Vitamin D Testing Policy

<b><u>Z79.891</u></b>	<b><u>Long term (current) use of opiate analgesic</u></b>
<b><u>Z79.899</u></b>	<b><u>Other long term (current) drug therapy</u></b>

**E55.9\* If more than one LCD-listed condition contributes to vitamin D deficiency in a given patient and/or is improved by vitamin D administration, coders should use: ICD-10 E55.9 UNSPECIFIED VITAMIN D DEFICIENCY. This code should not be used for any other indication. E83.50\* Use only for HYPERCALCIURIA**

**\*Osteopenia should be reported using ICD-10-CM codes M85.80, M85.831-M85.839, M85.851-M85.859, M85.88, M85.89, M85.9 or M89.9**

**The following ICD-10-CM codes support the medical necessity of CPT code 82652**

<b><u>E55.0</u></b>	<b><u>Rickets, active</u></b>
<b><u>E55.9</u></b>	<b><u>Vitamin D deficiency, unspecified</u></b>
<b><u>E83.50*</u></b>	<b><u>Unspecified disorder of calcium metabolism</u></b>
<b><u>E83.52*</u></b>	<b><u>Hypercalcemia</u></b>
<b><u>M83.0</u></b>	<b><u>Puerperal osteomalacia</u></b>
<b><u>M83.1</u></b>	<b><u>Senile osteomalacia</u></b>
<b><u>M83.2</u></b>	<b><u>Adult osteomalacia due to malabsorption</u></b>
<b><u>M83.3</u></b>	<b><u>Adult osteomalacia due to malnutrition</u></b>
<b><u>M83.4</u></b>	<b><u>Aluminum bone disease</u></b>
<b><u>M83.5</u></b>	<b><u>Other drug-induced osteomalacia in adults</u></b>
<b><u>M83.8</u></b>	<b><u>Other adult osteomalacia</u></b>
<b><u>M83.9*</u></b>	<b><u>Adult osteomalacia, unspecified</u></b>
<b><u>N20.0</u></b>	<b><u>Calculus of kidney</u></b>
<b><u>N20.1</u></b>	<b><u>Calculus of ureter</u></b>
<b><u>N20.2</u></b>	<b><u>Calculus of kidney with calculus of ureter</u></b>
<b><u>N20.9</u></b>	<b><u>Urinary calculus, unspecified</u></b>
<b><u>N22</u></b>	<b><u>Calculus of urinary tract in diseases classified elsewhere</u></b>

**ICD-10 Codes that DO NOT Support Medical Necessity Group 1 Paragraph:**



## CLINICAL POLICY

### Vitamin D Testing Policy

**All ICD-10-CM codes not listed in this policy under ICD-10-CM Codes that Support Medical Necessity above.**

<b><u>Reviews, Revisions, and Approvals</u></b>	<b><u>Date</u></b>	<b><u>Approval Date</u></b>
<b><u>Policy Created</u></b>	<b><u>8/20</u></b>	

### References

1. **Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism, Volume 96, Issue 7, 1 July 2011, Pages 1911–1930.**  
Accessed Oct 242018. Available at: <https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2011-0385>
2. **United States Preventive Services Task Force. Vitamin D Deficiency: Screening November 2014**

### Important Reminder

**This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.**

**The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.**

**This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.**

## CLINICAL POLICY

### Vitamin D Testing Policy

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

©2020 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.